Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by narmacon Jan 19, 2022 8:26am
261 Views
Post# 34331862

RE:RE:Commencement of Patient Enrollment/Dosing in Phase 2b trial

RE:RE:Commencement of Patient Enrollment/Dosing in Phase 2b trialPurdy well on the mark sj1,,,,,,,however if they accidentally do get good numbers in any form we might get a bump up in share price........I see a few media outlets have picked up the C19 dosing story,,,,one very important point that was not made clear to readers is that apabetalone also repairs damage to tissue from C19,,,,,,or is that NOT important and gives thie treatment a leg up on any other pill or injection out there,,,,,but then of course,,,Pinocchio with his dementia and the team with their lack of understanding might be retracting that notion!!!!!,,still RVX is in a pitiful situation!
<< Previous
Bullboard Posts
Next >>